10:25 AM EDT, 07/29/2025 (MT Newswires) -- Atossa Therapeutics ( ATOS ) shares were up Tuesday after the company said the US Food and Drug Administration issued constructive, "positive" feedback for the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of metastatic breast cancer.

FDA's feedback further paves the way for a potential investigational new drug application submission targeted for Q4, Atossa Therapeutics ( ATOS ) said.

Looking ahead, the biopharmaceutical company said it will unveil plans for the overall trial design and target patient population in the coming weeks.

Price: 0.91, Change: +0.09, Percent Change: +11.47